COMPASS THERAPEUTICS, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
COMPASS THERAPEUTICS, INC. (CMPX) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $50.62 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2022-03-18
- COMPASS THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2021-12-31 was $0.00.
- COMPASS THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2021-09-30 was $0.00.
- COMPASS THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2020-12-31 was $0.00.
- COMPASS THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2020-09-30 was $0.00.
- COMPASS THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2021 was $50.62M.
- COMPASS THERAPEUTICS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2020 was $0.00.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $50.62M 10-K · filed 2022-03-18 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $50.62M 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | $50.62M 10-Q · filed 2021-08-16 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |